Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
MeMed Ltd., leader des solutions de diagnostic basées sur la réponse de l'hôte, a annoncé aujourd'hui avoir reçu 2,5 millions d'euros sous forme de...
MeMed Ltd., a leader in host response-based diagnostic solutions, today announced that it has received €2.5 million in non-dilutive funding from the...
MeMed Ltd., ein führender Anbieter von Host-Response-basierten Diagnoselösungen, gab heute bekannt, dass er vom Europäischen Innovationsrat (EIC) 2,5 ...
MeMed Ltd., un leader dans le domaine des solutions de diagnostic axées sur les maladies infectieuses et la réaction de l'hôte, a annoncé aujourd'hui ...
MeMed Ltd., ein führendes Unternehmen von auf Wirtsimmunantworten basierenden Diagnoselösungen, gab heute den Beitritt von Dr. Frédéric Sweeney zu...
MeMed Ltd., a leader in host response-based diagnostic solutions, today announced the addition of Dr. Frédéric Sweeney to its executive team as Chief ...
Bedrijf wordt erkend vanwege nieuwe oplossing van groeiende dreiging van antibioticaresistentie HAIFA, Israël, 2 juli 2019 /PRNewswire/ - //MeMed Ltd....
MeMed Ltd., sviluppatore di uno strumento diagnostico all'avanguardia basato sul sistema immunitario che distingue tra infezioni batteriche e virali...
MeMed Ltd., Entwickler einer hochmodernen, auf dem Immunsystem basierenden Diagnostik, die zwischen bakteriellen und viralen Infektionen am...
MeMed Ltd., le développeur d'un diagnostic de pointe basé sur le système immunitaire capable de différencier les infections bactériennes des...
MeMed Ltd., the developer of a cutting-edge immune system-based diagnostic that distinguishes between bacterial and viral infections at the point of...
ImmunoXpert a le potentiel d'améliorer la prise en charge du patient et de réduire la résistance aux médicaments causée par la surconsommation...
Die Nutzung von ImmunoXpert weißt das Potenzial auf, das Patientenmanagement zu verbessern und die Arzneimittelresistenz aufgrund von übermäßiger...
- Lancet Infectious Diseases publica un estudio independiente de doble ciego que valida la capacidad del test sanguíneo Immunoxpert™ de MeMed para...
A MeMed Ltd. anunciou hoje a publicação, no Lancet Infectious Diseases, dos resultados do OPPORTUNITY, um estudo clínico internacional multicêntrico, ...
MeMed Ltd. anunció hoy la publicación Lancet Infectious Diseases de los resultados de OPPORTUNITY, un estudio clínico multicentro internacional...
Use of ImmunoXpert has the potential to improve patient management and reduce drug resistance due to antibiotic overuse ImmunoXpert significantly...
MeMed Ltd. announced today its commitment to supporting the initiative of the Centers for Disease Control and Prevention (CDC) to raise awareness of...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.